Kempen starts Inventiva with 'buy' citing encouraging liver disease drug trial results

Inventiva SA

02/12/2025 10:44

** Shares in French biotech firm Inventiva IVAA.PA rise 4.2% after Van Lanschot Kempen initiates coverage with "buy"

** The broker highlights strong 24-week trial results for lead drug lanifibranor in MASH liver disease, showing fibrosis improvement

** "With longer treatment duration we expect a deeper response rate, particularly on fibrosis improvement that could be paradigm shifting," Kempen says

** The brokerage sees 72-week phase 3 topline data for lanifibranor, due in Q2 2026, as key catalyst for Inventiva shares

** Kempen sets PT at 16 euros

** Out of 10 analysts that cover Inventiva, all rate the stock "strong buy" or "buy"​ - LSEG data

(Reporting by Lucie Barbier)

((Email: lucie.barbier@thomsonreuters.com))